NXTC – Nextcure Inc
Float Short %
1.71
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
1.37
EPS Last/This Y
10.15
EPS This/Next Y
5.5
Price
12.86
Target Price
17.67
Analyst Recom
1
Performance Q
7.29
Relative Volume
0.61
Beta
1.55
Ticker: NXTC
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | NXTC | 12.47 | N/A | N/A | 0 |
| 2025-12-29 | NXTC | 13.2 | N/A | N/A | 0 |
| 2025-12-30 | NXTC | 13.95 | N/A | N/A | 0 |
| 2025-12-31 | NXTC | 14.26 | N/A | N/A | 0 |
| 2026-01-02 | NXTC | 13.29 | N/A | N/A | 0 |
| 2026-01-05 | NXTC | 13.6 | N/A | N/A | 0 |
| 2026-01-06 | NXTC | 13.11 | N/A | N/A | 0 |
| 2026-01-07 | NXTC | 13.76 | N/A | N/A | 0 |
| 2026-01-08 | NXTC | 13.59 | N/A | N/A | 0 |
| 2026-01-09 | NXTC | 13.44 | N/A | N/A | 0 |
| 2026-01-12 | NXTC | 13.13 | N/A | N/A | 0 |
| 2026-01-13 | NXTC | 13.4 | N/A | N/A | 0 |
| 2026-01-14 | NXTC | 12.89 | N/A | N/A | 0 |
| 2026-01-15 | NXTC | 12.85 | N/A | N/A | 0 |
| 2026-01-16 | NXTC | 12.96 | N/A | N/A | 0 |
| 2026-01-20 | NXTC | 13.45 | N/A | N/A | 0 |
| 2026-01-21 | NXTC | 13 | N/A | N/A | 0 |
| 2026-01-22 | NXTC | 12.64 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | NXTC | 12.62 | 53.5 | 14.7 | -13.73 |
| 2025-12-29 | NXTC | 13.24 | 53.5 | 10.9 | -13.73 |
| 2025-12-30 | NXTC | 13.96 | 53.5 | 6.4 | -13.73 |
| 2025-12-31 | NXTC | 14.34 | 53.5 | 9.2 | -13.73 |
| 2026-01-02 | NXTC | 13.17 | 53.5 | 19.7 | -13.73 |
| 2026-01-05 | NXTC | 13.60 | 53.5 | 10.3 | -13.73 |
| 2026-01-06 | NXTC | 13.15 | 53.5 | 16.2 | -13.73 |
| 2026-01-07 | NXTC | 13.99 | 53.5 | 6.9 | -13.73 |
| 2026-01-08 | NXTC | 13.45 | 53.5 | 15.3 | -13.73 |
| 2026-01-09 | NXTC | 13.30 | 53.5 | 15.0 | -13.73 |
| 2026-01-12 | NXTC | 13.40 | 53.5 | 13.2 | -13.73 |
| 2026-01-13 | NXTC | 13.17 | 53.5 | 15.0 | -13.73 |
| 2026-01-14 | NXTC | 13.00 | 53.5 | 16.0 | -13.73 |
| 2026-01-15 | NXTC | 12.87 | 53.5 | 12.5 | -13.73 |
| 2026-01-16 | NXTC | 13.08 | 53.5 | 10.0 | -13.73 |
| 2026-01-20 | NXTC | 13.27 | 53.5 | 9.1 | -13.73 |
| 2026-01-21 | NXTC | 13.16 | 53.5 | 14.0 | -13.73 |
| 2026-01-22 | NXTC | 12.86 | 53.5 | 13.8 | -13.73 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | NXTC | 0.00 | -0.25 | 1.41 |
| 2025-12-29 | NXTC | 0.00 | -0.25 | 1.41 |
| 2025-12-30 | NXTC | 0.00 | -0.25 | 1.41 |
| 2025-12-31 | NXTC | 0.00 | -0.25 | 1.41 |
| 2026-01-02 | NXTC | 0.00 | -0.25 | 1.41 |
| 2026-01-05 | NXTC | 0.00 | 7.18 | 1.41 |
| 2026-01-06 | NXTC | 0.00 | 7.18 | 1.41 |
| 2026-01-07 | NXTC | 0.00 | 7.18 | 1.41 |
| 2026-01-08 | NXTC | 0.00 | 7.18 | 1.41 |
| 2026-01-09 | NXTC | 0.00 | 7.18 | 1.41 |
| 2026-01-12 | NXTC | 0.00 | 7.18 | 1.41 |
| 2026-01-13 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-14 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-15 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-16 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-20 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-21 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-22 | NXTC | 0.00 | 7.18 | 1.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-3.22
Avg. EPS Est. Current Quarter
-2.29
Avg. EPS Est. Next Quarter
-1.85
Insider Transactions
Institutional Transactions
7.18
Beta
1.55
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
3
Growth Score
19
Sentiment Score
81
Actual DrawDown %
92.6
Max Drawdown 5-Year %
-98.1
Target Price
17.67
P/E
Forward P/E
PEG
P/S
P/B
1.43
P/Free Cash Flow
EPS
-24.19
Average EPS Est. Cur. Y
-13.73
EPS Next Y. (Est.)
-8.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.61
Return on Equity vs Sector %
-272.6
Return on Equity vs Industry %
-256.7
EPS 1 7Days Diff
0.6
EPS 1 30Days Diff
1.86
EBIT Estimation
13.8
NextCure, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading